Mechanism of Action
Overview of key disease mechanisms within tumor cells and the MoA of avelumab, an anti-programmed death ligand-1 (PD-L1) antibody | Slide Deck
JAVELIN Bladder 100 Overview
Summary of key data from the JAVELIN Bladder 100 trial including additional subgroup and patient-reported outcomes (PRO) analyses | Slide Deck
JAVELIN Merkel 200 Overview
Summary of key data from the JAVELIN Merkel 200 trial including both 2L and 1L data | Slide Deck
JAVELIN Renal 101 Overview
Summary of key data from the JAVELIN Renal 101 trial | Slide Deck
BAVENCIO and CoverOne are registered trademarks of Merck KGaA, Darmstadt, Germany or its affiliates.
This site is intended for US healthcare professionals only.
DISCLAIMER: This site contains medical information that is intended for healthcare providers of the United States only. The medical information contained on this site is not meant to substitute for the advice provided by a medical professional. Canadian residents should consult the EMD Serono Canada Inc. website at www.emdserono.ca for information on products and services approved in Canada. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy.
EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany, in the United States and Canada.
US-MULNP-00023 09/24
By clicking this link, you are leaving medical.emdserono.com. Please, note that this link will take you to a website on which different Privacy Policy and Conditions may apply. EMD Serono accepts no responsibility for websites not controlled directly by us. Please check Privacy Policy and Conditions of the linked website.
Help us direct you to the right information by selecting one of the following options: